BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1066 related articles for article (PubMed ID: 19016372)

  • 1. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.
    Sakamoto M; Nakajima J; Murakawa T; Fukami T; Yoshida Y; Murayama T; Takamoto S; Matsushita H; Kakimi K
    J Immunother; 2011 Mar; 34(2):202-11. PubMed ID: 21304399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
    Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
    Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
    Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients.
    Gaafar A; Aljurf MD; Al-Sulaiman A; Iqniebi A; Manogaran PS; Mohamed GE; Al-Sayed A; Alzahrani H; Alsharif F; Mohareb F; Ajarim D; Tabakhi A; Al-Hussein K
    Exp Hematol; 2009 Jul; 37(7):838-48. PubMed ID: 19446661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2.
    Li W; Kubo S; Okuda A; Yamamoto H; Ueda H; Tanaka T; Nakamura H; Yamanishi H; Terada N; Okamura H
    J Immunother; 2010 Apr; 33(3):287-96. PubMed ID: 20445349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells.
    Nakajima J; Murakawa T; Fukami T; Goto S; Kaneko T; Yoshida Y; Takamoto S; Kakimi K
    Eur J Cardiothorac Surg; 2010 May; 37(5):1191-7. PubMed ID: 20137969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
    Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C
    Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach.
    Dokouhaki P; Han M; Joe B; Li M; Johnston MR; Tsao MS; Zhang L
    Cancer Lett; 2010 Nov; 297(1):126-36. PubMed ID: 20537791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
    Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
    Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate anti-breast cancer immunity of apoptosis-resistant human gammadelta-T cells.
    Guo BL; Liu Z; Aldrich WA; Lopez RD
    Breast Cancer Res Treat; 2005 Sep; 93(2):169-75. PubMed ID: 16187237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
    Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K
    Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
    Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
    Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.
    Muraro M; Mereuta OM; Carraro F; Madon E; Fagioli F
    Cell Immunol; 2007 Oct; 249(2):63-72. PubMed ID: 18163982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
    Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
    Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma.
    Burjanadzé M; Condomines M; Reme T; Quittet P; Latry P; Lugagne C; Romagne F; Morel Y; Rossi JF; Klein B; Lu ZY
    Br J Haematol; 2007 Oct; 139(2):206-16. PubMed ID: 17897296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes.
    Todaro M; D'Asaro M; Caccamo N; Iovino F; Francipane MG; Meraviglia S; Orlando V; La Mendola C; Gulotta G; Salerno A; Dieli F; Stassi G
    J Immunol; 2009 Jun; 182(11):7287-96. PubMed ID: 19454726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of culture medium on the expansion of T cells for immunotherapy.
    Sato K; Kondo M; Sakuta K; Hosoi A; Noji S; Sugiura M; Yoshida Y; Kakimi K
    Cytotherapy; 2009; 11(7):936-46. PubMed ID: 19903105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of cytotoxic T lymphocytes by CEA peptide-pulsed γδ T-cells isolated from patients with advanced cancer.
    Yamasaki A; Onishi H; Morisaki T; Katano M
    Anticancer Res; 2011 Jul; 31(7):2419-24. PubMed ID: 21873153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
    Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A
    Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.